Acipimox to Improve Hyperlipidemia and Insulin Sensitivity Associated With HIV

Completed · Not applicable

Conditions studied: Insulin Resistance, Cardiovascular Diseases, Heart Diseases, HIV Infections, Hypertriglyceridemia, Hyperlipidemia

In brief

The purpose of this study is to test whether chronic administration of the drug acipimox will improve hyperlipidemia and insulin sensitivity among HIV infected patients experiencing highly active antiretroviral therapy (HAART) associated metabolic disturbances.

Key facts

Study ID
NCT00246402
Run by
National Heart, Lung, and Blood Institute (NHLBI)
People needed
30
Starts
2002-09-01
Expected to finish
2006-08-01
Last updated by the study team
2014-05-15

Who can join

Age: 18 and older, up to 65. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

You may not qualify if…

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.